Evidence map›Paper›PMID 40216609›Full record

ArticlePituitary2025

Pasireotide as first line medical therapy for selected patients with acromegaly.

Nicoleta C Olarescu, Anders P Jørgensen, Shahriar Atai, Markus K H Wiedmann, Daniel Dahlberg, Jens Bollerslev, Ansgar Heck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nicoleta C OlarescuSection of Specialised Endocrinology, Clinic of Medicine, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0009-0004-9436-539X
Anders P JørgensenSection of Specialised Endocrinology, Clinic of Medicine, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0002-1246-9194
Shahriar AtaiSection of Specialised Endocrinology, Clinic of Medicine, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0009-0005-6818-1076
Markus K H WiedmannDepartment of Neurosurgery, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0002-4172-4115
Daniel DahlbergDepartment of Neurosurgery, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0001-5278-1978
Jens BollerslevSection of Specialised Endocrinology, Clinic of Medicine, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0002-0654-4610
Ansgar HeckSection of Specialised Endocrinology, Clinic of Medicine, Oslo University Hospital, Oslo, Norway. anshec@ous-hf.no.ORCID https://orcid.org/0000-0002-3443-884X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeIn acromegaly, growth hormone (GH) excess and pituitary tumours are typically managed through transsphenoidal surgery, often in combination with somatostatin receptor ligands (SRLs) given either before or following surgery. Although first-generation SRLs (lanreotide and octreotide) are efficacious in many patients, some exhibit resistance.

methodsWe present the efficacy of the second-generation SRL, pasireotide, in six patients anticipated to be resistant to first-generation SRLs. The patients had large, hyperintense tumors on T2-weighted MRI and sparse granulation pattern by histology.

resultsOver three to eight months, pasireotide reduced tumour volume in all patients and improved GH and IGF-1 levels. Visual field defects normalised. Despite hyperglycemia, requiring antidiabetic treatment in two patients, pasireotide proved effective as a first pharmacological therapy.

conclusionThis series supports the use of pasireotide for rapid tumour control and GH reduction, in selected patients with complex and large tumours, likely to be resistant to first-generation SRLs. This approach expands the therapeutic options for managing the most challenging cases enhancing the potential for other subsequent treatment modalities.

Indexed as

AcromegalySomatostatinAdultAgedFemaleHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleMiddle AgedOctreotidePituitary NeoplasmsHuman Growth HormoneInsulin-Like Growth Factor IOctreotidepasireotideSomatostatinOctreotide testPituitarySomatostatin analogueSomatostatin receptor ligand

Identifiers

PMID40216609
PMCPMC11991941

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.